Giuseppe
Emeritus
Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe (Euro Surveill., abstract, edited)
[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19688">Eurosurveillance - View Article</cite>. Abstract, edited.]
Eurosurveillance, Volume 15, Issue 41, 14 October 2010
Review articles
Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe
R K?ck 1,2, K Becker 2, B Cookson 3, J E van Gemert-Pijnen 4, S Harbarth 5,6, J Kluytmans 7,8, M Mielke 9, G Peters 2, R L Skov 10, M J Struelens 11,12, E Tacconelli 13, A Navarro Torn? 12, W Witte 14, A W Friedrich 1
1. Institute of Hygiene, University Hospital Muenster, Muenster, Germany
2. Institute of Medical Microbiology, University Hospital Muenster, Muenster, Germany
3. Laboratory of Healthcare Associated Infections, Centre for Infections, Health Protection Agency, London, United Kingdom
4. Faculty of Behavioural Sciences, University of Twente, Enschede, the Netherlands
5. Infection Control Program, University Hospitals of Geneva, Geneva, Switzerland
6. University of Geneva Medical School, Geneva, Switzerland
7. VU University Medical Centre, Amsterdam
8. Amphia Hospital, Breda, the Netherlands
9. Robert Koch Institute, Berlin, Germany
10. Statens Serum Institut (SSI, National Centre for Infectious Diseases), Copenhagen, Denmark
11. Department of Microbiology, Universit? Libre de Bruxelles, H?pital Erasme, Brussels, Belgium (affiliation where the work was started)
12. Scientific Advice Unit, European Centre for Disease Prevention and Control, Stockholm, Sweden
13. Department of Infectious Diseases, Universit? Cattolica Sacro Cuore, Rome, Italy
14. National Reference Centre for Staphylococci, Robert Koch Institute, Wernigerode, Germany
Citation style for this article: K?ck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, Mielke M, Peters G, Skov RL, Struelens MJ, Tacconelli E, Navarro Torn? A, Witte W, Friedrich AW. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41)
ii=19688. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19688
Date of submission: 15 June 2010
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare- and community-associated infections worldwide. Within the healthcare setting alone, MRSA infections are estimated to affect more than 150,000 patients annually in the European Union (EU), resulting in attributable extra in-hospital costs of EUR 380 million for EU healthcare systems. Pan-European surveillance data on bloodstream infections show marked variability among EU Member States in the proportion of S. aureus that are methicillin-resistant, ranging from less than 1% to more than 50%. In the past five years, the MRSA bacteraemia rates have decreased significantly in 10 EU countries with higher endemic rates of MRSA infections. In addition to healthcare-associated infections, new MRSA strains have recently emerged as community- and livestock-associated human pathogens in most EU Member States. The prevention and control of MRSA have therefore been identified as public health priorities in the EU. In this review, we describe the current burden of MRSA infections in healthcare and community settings across Europe and outline the main threats caused by recent changes in the epidemiology of MRSA. Thereby, we aim at identifying unmet needs of surveillance, prevention and control of MRSA in Europe.
-
------
[Source: Eurosurveillance, full text: <cite cite="http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19688">Eurosurveillance - View Article</cite>. Abstract, edited.]
Eurosurveillance, Volume 15, Issue 41, 14 October 2010
Review articles
Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe
R K?ck 1,2, K Becker 2, B Cookson 3, J E van Gemert-Pijnen 4, S Harbarth 5,6, J Kluytmans 7,8, M Mielke 9, G Peters 2, R L Skov 10, M J Struelens 11,12, E Tacconelli 13, A Navarro Torn? 12, W Witte 14, A W Friedrich 1
1. Institute of Hygiene, University Hospital Muenster, Muenster, Germany
2. Institute of Medical Microbiology, University Hospital Muenster, Muenster, Germany
3. Laboratory of Healthcare Associated Infections, Centre for Infections, Health Protection Agency, London, United Kingdom
4. Faculty of Behavioural Sciences, University of Twente, Enschede, the Netherlands
5. Infection Control Program, University Hospitals of Geneva, Geneva, Switzerland
6. University of Geneva Medical School, Geneva, Switzerland
7. VU University Medical Centre, Amsterdam
8. Amphia Hospital, Breda, the Netherlands
9. Robert Koch Institute, Berlin, Germany
10. Statens Serum Institut (SSI, National Centre for Infectious Diseases), Copenhagen, Denmark
11. Department of Microbiology, Universit? Libre de Bruxelles, H?pital Erasme, Brussels, Belgium (affiliation where the work was started)
12. Scientific Advice Unit, European Centre for Disease Prevention and Control, Stockholm, Sweden
13. Department of Infectious Diseases, Universit? Cattolica Sacro Cuore, Rome, Italy
14. National Reference Centre for Staphylococci, Robert Koch Institute, Wernigerode, Germany
Citation style for this article: K?ck R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, Mielke M, Peters G, Skov RL, Struelens MJ, Tacconelli E, Navarro Torn? A, Witte W, Friedrich AW. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41)
ii=19688. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19688Date of submission: 15 June 2010
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare- and community-associated infections worldwide. Within the healthcare setting alone, MRSA infections are estimated to affect more than 150,000 patients annually in the European Union (EU), resulting in attributable extra in-hospital costs of EUR 380 million for EU healthcare systems. Pan-European surveillance data on bloodstream infections show marked variability among EU Member States in the proportion of S. aureus that are methicillin-resistant, ranging from less than 1% to more than 50%. In the past five years, the MRSA bacteraemia rates have decreased significantly in 10 EU countries with higher endemic rates of MRSA infections. In addition to healthcare-associated infections, new MRSA strains have recently emerged as community- and livestock-associated human pathogens in most EU Member States. The prevention and control of MRSA have therefore been identified as public health priorities in the EU. In this review, we describe the current burden of MRSA infections in healthcare and community settings across Europe and outline the main threats caused by recent changes in the epidemiology of MRSA. Thereby, we aim at identifying unmet needs of surveillance, prevention and control of MRSA in Europe.
-
------
